Maxim Group Upgrades Vertex Pharmaceuticals to Buy, Announces $575 Price Target

Maxim Group analyst Naz Rahman has upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from a Hold rating to a Buy rating. Additionally, a price target of $575 has been announced for the company's stock.